Merge Healthcare (NASDAQ:MRGE) had its target price boosted by Topeka Capital Markets from $4.50 to $5.25 in a report issued on Monday. They currently have a buy rating on the stock.
Separately, analysts at Zacks reiterated a neutral rating and set a $4.25 price target on shares of Merge Healthcare in a research note on Tuesday, March 10th.
Merge Healthcare (NASDAQ:MRGE) opened at 4.47 on Monday. Merge Healthcare has a 52 week low of $1.97 and a 52 week high of $4.73. The stock’s 50-day moving average is $4. and its 200-day moving average is $3.. The company’s market cap is $431.35 million.
Merge Healthcare (NASDAQ:MRGE) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.04 by $0.01. Analysts expect that Merge Healthcare will post $0.21 EPS for the current fiscal year.
Merge Healthcare Incorporated (NASDAQ:MRGE) develops software solutions that facilitate the sharing of images to create an electronic healthcare experience for patients and physicians. Its solutions are designed to help solve some of the challenges in health information exchange, such as the incorporation of medical images and diagnostic information into broader health information technology (IT) applications and the interoperability of software solutions.
